Floatz logo

ar-42

Prolymphocytic Leukemia

Amir MortazaviSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Fludarabine
Center for International Blood and Marrow Transplant Research
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
FILGRASTIM
Center for International Blood and Marrow Transplant Research
Phase 2BB
TACROLIMUS
Center for International Blood and Marrow Transplant Research
Phase 2BB

View all 50 →

Same molecule, other indications

ar-42 is also rated in:

plasma cell myelomaDormant
CCC
Indicative ·
52 / 100
View asset →
primary cutaneous B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →